Preview
• Castration-refractory prostate cancer (CRPC) is defined as progression despite ongoing primary androgen deprivation therapy • Paradoxical androgen receptor stimulation can be seen and will respond to anti-androgen withdrawal • Steroids offer only limitedly-effective second-line therapy and one has to be aware of side effects • Selective blocking of cytochrome P17 with abiraterone opens a novel treatment option but is still an experimental approach.
Chapter. 1025 words. Illustrated.
Subjects: Clinical Oncology
Go to Oxford Medicine Online » abstract
Full text: subscription required
How to subscribe Recommend to my Librarian
Buy this work at Oxford University Press »
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.
